Top Preclinical Cro Companies in South Korea

JNPMEDI is focused on enhancing clinical trial solutions through digital technologies like blockchain and cloud, which aligns with the advancement of preclinical research. Their Maven clinical cloud solutions aim to improve the execution and management of clinical trials, making them a valuable partner for those involved in clinical research.

Spidercore is focused on enhancing gene therapy through its hyper-scale AI engine, which analyzes the physicochemical properties of nucleotides to discover reliable gene therapies. Their AI platform aims to improve clinical decision-making, ultimately enhancing patient outcomes and making biomedical care more accessible and affordable.

The company emphasizes its commitment to reducing the risks associated with new drug development through an open innovation model, offering a comprehensive one-stop solution that includes rapid screening of drug candidates, advanced vivarium services, and thorough efficacy and safety evaluations. With state-of-the-art facilities and a focus on compliance with GMP standards, they position themselves as a strong partner in the preclinical phase of drug development.

MxT Biotech is advancing its mission through collaborations that enhance the delivery of external cargos like plasmid DNA and CRISPR-Cas9 RNPs into primary cells using their Hydroporator® platform.

Brightonix Imaging is a global leader in innovative biomedical imaging solutions, providing advanced preclinical devices like the SimPET-XL and M7-SimPET™, which are essential for enhancing research in preclinical settings.

MediHeroes is a B2B medical platform that connects suppliers of quality medical products and services with buyers, addressing concerns about product verification and seller trustworthiness. They offer a range of membership benefits and training programs to support businesses in expanding their reach globally.

Onegene Biotechnology is a preclinical stage biotech focused on innovative multi-target drug development, particularly through their flagship program OGB21502, a tetraspecific drug for NASH treatment. With expertise in disease microenvironments and a commitment to advancing research, they are poised to make significant contributions to the treatment of complex diseases.

At BIORCHESTRA, the focus is on developing innovative RNA medicines and delivery systems that address unmet medical needs, particularly in neurodegenerative and rare diseases of the Central Nervous System. This aligns with the preclinical research phase, where their best-in-class technology enhances the targeted delivery of RNA therapeutics.

The company focuses on early detection of health risks through retinal scans, utilizing AI diagnostic solutions like Reti-Intelligence to predict cardiovascular and other diseases. Their approach emphasizes preventive healthcare by identifying risks before symptoms manifest.

The company is advancing personalized and regenerative medicine through its innovative bioprinting platform, which enables the creation of realistic in vitro cancer tissues and organoids for rapid testing of treatments. This high-throughput technology is paving the way for more effective and humane alternatives to traditional testing methods.